Merus N.V. announced on December 1, 2024, the publication of an abstract regarding petosemtamab in previously treated (2L+) recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). The abstract was published on the European Society for Medical Oncology (ESMO®) Asia Congress website.
The abstract presents updated interim clinical data on petosemtamab from both the initial expansion cohort (1500 mg) and a new dose-comparison cohort (1100 mg vs. 1500 mg) in 2L+ HNSCC. This data is slated for presentation at the ESMO® Asia Congress 2024, held from December 6-8, 2024.
Merus plans to host a conference call on December 7, 2024, to discuss the full data set, which will include additional patients evaluable for response and more mature duration of treatment information. This publication sets the stage for a detailed review of petosemtamab's continued clinical activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.